Shelton Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Shelton Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-74,850	Closed	-$3.04M	–	738
2022 Q4	$3.04M	Sell	74,850 -57,000	-43%	-$3.02M	0.32%	108
2022 Q3	$8.62M	Sell	131,850 -18,150	-12%	-$1.32M	0.41%	62
2022 Q2	$9.12M	Hold	150,000	–	–	0.41%	62
2022 Q1	$9.42M	Hold	150,000	–	–	0.35%	69
2021 Q4	$11.4M	Buy	150,000 +28,000	+23%	+$2.45M	0.4%	52
2021 Q3	$13.7M	Buy	122,000 +34,000	+39%	+$4.27M	0.53%	37
2021 Q2	$14.2M	Buy	88,000 +8,000	+10%	+$973K	0.54%	36
2021 Q1	$9.75M	Buy	80,000 +42,700	+114%	+$6.45M	0.34%	64
2020 Q4	$5.71M	Buy	37,300 +5,300	+17%	+$626K	0.26%	80
2020 Q3	$2.68M	Hold	32,000	–	–	0.11%	204
2020 Q2	$2.35M	Hold	32,000	–	–	0.13%	157
2020 Q1	$1.36M	Buy	32,000 +9,000	+39%	+$465K	0.1%	189
2019 Q4	$1.4M	Buy	23,000 +1,000	+5%	+$54.6K	0.08%	204
2019 Q3	$902K	Hold	22,000	–	–	0.05%	238
2019 Q2	$1.04M	Buy	22,000 +21,382	+3,460%	+$855K	0.06%	231
2019 Q1	$17.3K	Sell	618 -12,182	-95%	-$421K	0.07%	252
2018 Q4	$366K	Buy	12,800 +5,300	+71%	+$184K	0.02%	397
2018 Q3	$333K	Hold	7,500	–	–	0.02%	538
2018 Q2	$441K	Buy	+7,500	New	+$427K	0.03%	397

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Shelton Capital Management's CRSP Position: Q1 2023 in Review

Shelton Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 74,850 shares — an estimated $3.04M sold.

Shelton Capital Management first reported a position in CRSP in Q2 2018 and held it in 19 quarters. The position peaked at $14.2M in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Shelton Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
Shelton Capital Management sold 74,850 CRISPR Therapeutics shares in Q1 2023, an estimated $3.04M.
Shelton Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 19 quarters.
Shelton Capital Management's CRISPR Therapeutics position peaked at $14.2M in Q2 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Shelton Capital Management's 13F filing for Q1 2023, filed 11 May 2023.